OTCMKTS:SHTDF Sinopharm Group (SHTDF) Stock Price, News & Analysis $1.80 -0.21 (-10.59%) As of 10:00 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Sinopharm Group Stock (OTCMKTS:SHTDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sinopharm Group alerts:Sign Up Key Stats Today's Range$1.80▼$1.8050-Day Range$1.80▼$2.1552-Week Range$1.72▼$2.70Volume387 shsAverage Volume70,543 shsMarket CapitalizationN/AP/E Ratio1.80Dividend Yield14.44%Price TargetN/AConsensus RatingN/A Company Overview Sinopharm Group Co., Ltd. is a China-based healthcare company focused primarily on pharmaceutical and medical product distribution. Through its distribution network, the company supplies prescription medicines, traditional Chinese medicines, vaccines, medical devices, diagnostic products and other healthcare-related goods to hospitals, pharmacies and other medical institutions. The company also operates pharmaceutical retail businesses and provides related supply-chain services, including warehousing, logistics, procurement and inventory management. Its distribution operations serve customers across multiple regions of mainland China, supporting the delivery of healthcare products from manufacturers to medical and retail channels. Sinopharm Group is part of China National Pharmaceutical Group Corporation, commonly known as Sinopharm, one of China's major healthcare groups. The company was established in 2003 and its shares have been listed on the Hong Kong Stock Exchange since 2009. In addition to distribution and retail, its broader business activities include pharmaceutical manufacturing and healthcare-related services through affiliated operations.AI Generated. May Contain Errors. Read More Sinopharm Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreSHTDF MarketRank™: 0.581848914315 of 5 starsSinopharm Group scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sinopharm Group. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sinopharm Group is 1.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Sinopharm Group is 1.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 177.31. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverSinopharm Group has a short interest ratio ("days to cover") of 21.42, which indicates bearish sentiment.Change versus previous monthShort interest in Sinopharm Group has recently increased by 0.41%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSinopharm Group pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSinopharm Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sinopharm Group is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Sinopharm Group's dividend. News and Social Media2.3 / 5News SentimentN/A News SentimentSinopharm Group has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sinopharm Group this week, compared to 0 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sinopharm Group insiders have not sold or bought any company stock.Percentage Held by Institutions16.47% of the stock of Sinopharm Group is held by institutions.Read more about Sinopharm Group's insider trading history. Receive SHTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SHTDF Stock News HeadlinesSinopharm Group (OTCMKTS:SHTDF) Shares Cross Below 200 Day Moving Average - What's Next?October 10, 2026 | americanbankingnews.comSinopharm Divests Controlling Stake in Guorui Pharmaceutical in Connected DealAugust 19, 2026 | tipranks.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 16 at 1:00 AM | Weiss Ratings (Ad)Sinopharm Reshapes Key Board Committees to Bolster GovernanceAugust 18, 2026 | tipranks.comSinopharm Board Sets August Meeting to Approve Interim ResultsAugust 7, 2026 | tipranks.comSinopharm Medical Device Unit Sees Profit Decline Amid Modest Revenue GrowthJuly 1, 2026 | theglobeandmail.comSinopharm Shareholders Approve 2025 Results and Final Dividend at AGMJune 18, 2026 | tipranks.comSinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset baseApril 26, 2026 | tipranks.comSee More Headlines SHTDF Stock Analysis - Frequently Asked Questions How have SHTDF shares performed this year? Sinopharm Group's stock was trading at $2.60 at the beginning of 2026. Since then, SHTDF shares have decreased by 30.8% and is now trading at $1.80. How do I buy shares of Sinopharm Group? Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryN/A Current SymbolOTCMKTS:SHTDF CIK1556605 Webwww.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees94,910Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.80 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:SHTDF) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinopharm Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.